WO2023161857 - BIFUNCTIONAL CYTOKINE COMPOSITIONS
National phase entry is expected:
Publication Number
WO/2023/161857
Publication Date
31.08.2023
International Application No.
PCT/IB2023/051691
International Filing Date
23.02.2023
Title **
[English]
BIFUNCTIONAL CYTOKINE COMPOSITIONS
[French]
COMPOSITIONS DE CYTOKINE BIFONCTIONNELLE
Applicants **
BRIGHT PEAK THERAPEUTICS AG
Inventors
PATTABIRAMAN, Vijaya Raghavan
KREFT, Bertolt
CARRALOT, Jean-Philippe
MOOSMANN, Philipp
Priority Data
63/313,248
23.02.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4628 | |
| EPO | Filing, Examination, Granting | 60374 | |
| Japan | Filing, Examination, Granting | 4141 | |
| South Korea | Filing, Examination, Granting | 6550 | |
| USA | Filing, Examination, Granting | 17390 |
Total:
93,083
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure relates to bifunctional cytokine compositions comprising first and second cytokines connected by a linker, as well as methods of making bifunctional cytokine compositions. The disclosure also relates to bifunctional cytokine compositions comprising interleukins, including interleukin-2, interleukin-7, and interleukin-18, as well as derivatives thereof.[French]
La présente divulgation concerne des compositions de cytokine bifonctionnelle comprenant des première et seconde cytokines reliées par un lieur, ainsi que des procédés de fabrication de compositions de cytokine bifonctionnelle. La divulgation concerne également des compositions de cytokine bifonctionnelles comprenant des interleukines, comprenant l'interleukine-2, l'interleukine-7 et l'interleukine-18, ainsi que des dérivés de celles-ci.